Vaginal Dryness: What Could Be Causing It

Estrogen Decline Is the Leading Cause

The single most frequent reason for vaginal dryness is a drop in circulating estrogen. Estrogen maintains vaginal epithelial thickness, blood flow, lubrication, and an acidic pH that protects against infection. When levels fall, the tissue thins, loses elasticity, and produces less moisture.

This process accelerates during the menopausal transition. The Study of Women's Health Across the Nation (SWAN), a longitudinal cohort of over 3,000 women, found that vaginal dryness prevalence rose from approximately 19% in the early reproductive years to 34% three years after the final menstrual period [1]. By five years postmenopause, the percentage climbs higher still. Unlike vasomotor symptoms (hot flashes), which tend to diminish over time, vaginal dryness is progressive. It does not resolve without intervention.

Estrogen decline is not limited to natural menopause. Surgical removal of both ovaries (bilateral oophorectomy) produces an immediate and severe estrogen deficit. Radiation to the pelvis, chemotherapy with alkylating agents, and GnRH agonist therapy for endometriosis or uterine fibroids all suppress ovarian function and can cause dryness in women decades before typical menopause age [2]. The 2020 North American Menopause Society (NAMS) position statement on hormone therapy notes that "genitourinary syndrome of menopause affects up to 84% of postmenopausal women and worsens progressively without treatment" [3].

GSM: More Than Just Dryness

In 2014, the International Society for the Study of Women's Sexual Health (ISSWSH) and NAMS jointly replaced the term "vulvovaginal atrophy" with genitourinary syndrome of menopause, or GSM [4]. The name change was not cosmetic. It reflected the recognition that estrogen loss affects the entire lower urogenital tract: vagina, vulva, urethra, and bladder.

GSM encompasses vaginal dryness alongside burning, irritation, dyspareunia (painful intercourse), urinary urgency, recurrent urinary tract infections, and post-coital bleeding. A woman may present with one symptom or several. Vaginal pH rises above 5.0 (normal premenopausal range is 3.5 to 4.5), and the epithelium becomes pale, smooth, and friable on examination [4].

The clinical significance of GSM deserves emphasis. A 2019 cross-sectional survey of 3,768 postmenopausal women published in Menopause found that 50% of those with moderate-to-severe GSM symptoms reported a negative impact on sexual satisfaction, and 29% reported avoiding intimacy entirely [5]. Despite this burden, the REVIVE (Real Women's Views of Treatment Options for Menopausal Vaginal Changes) survey showed that only 25% of affected women had sought medical care [6]. Barriers included embarrassment, the assumption that dryness is a normal part of aging that cannot be treated, and lack of clinician-initiated screening.

Dr. JoAnn Pinkerton, past executive director of NAMS, has stated: "Clinicians should proactively ask postmenopausal patients about vulvovaginal symptoms because most women will not bring it up on their own" [3].

Medications That Cause or Worsen Dryness

Several drug classes reduce vaginal lubrication through distinct mechanisms. Not every case of vaginal dryness traces back to menopause.

Antihistamines and anticholinergics. Diphenhydramine, cetirizine, and other antihistamines dry mucous membranes systemically, including vaginal tissue. Anticholinergic medications used for overactive bladder (oxybutynin, tolterodine) carry the same effect [7].

Selective serotonin reuptake inhibitors (SSRIs). Fluoxetine, sertraline, and paroxetine can reduce genital arousal and impair lubrication. A meta-analysis in the Journal of Clinical Psychiatry reported sexual dysfunction rates of 25.8% to 80.3% across SSRI trials, with decreased lubrication as a commonly cited complaint [8].

Combined hormonal contraceptives. Oral contraceptive pills suppress endogenous estradiol and increase sex hormone-binding globulin, which lowers free testosterone. Both changes may reduce vaginal lubrication. A 2006 study in the Journal of Sexual Medicine found that women on combined oral contraceptives had significantly lower levels of free testosterone and reported more vulvar discomfort than non-users [9].

Aromatase inhibitors. Anastrozole, letrozole, and exemestane, used in estrogen receptor-positive breast cancer, profoundly lower estrogen levels. Vaginal dryness occurs in 18% to 48% of women on aromatase inhibitor therapy, according to data from the ATAC and BIG 1-98 trials [10].

GnRH agonists and antagonists. Leuprolide, goserelin, and the newer oral GnRH antagonists (elagolix, relugolix) suppress ovarian estrogen production. Vaginal dryness is a predictable consequence and often requires concurrent low-dose hormonal add-back therapy [11].

Sjögren Syndrome and Autoimmune Causes

Sjögren syndrome is a systemic autoimmune disorder targeting exocrine glands. Dry eyes and dry mouth are the hallmark features, but vaginal dryness is a frequently overlooked component. A 2014 study in Clinical and Experimental Rheumatology found that 53% of women with primary Sjögren syndrome reported vaginal dryness, compared to 26% of age-matched controls [12].

The mechanism involves lymphocytic infiltration of Bartholin's glands and minor vestibular glands, reducing secretory output. Unlike estrogen-mediated dryness, Sjögren-associated dryness does not respond fully to local estrogen. Patients often need vaginal moisturizers, sometimes combined with systemic immunomodulatory treatment [12].

Other autoimmune conditions can contribute indirectly. Lupus (SLE), when treated with high-dose corticosteroids, may suppress gonadal function. Premature ovarian insufficiency (POI), which has autoimmune subtypes, causes estrogen deficiency in women under 40 and affects roughly 1% to 3.7% of women in that age group [13].

Dermatologic and Vulvar Conditions

Dryness that localizes specifically to the vulvar skin rather than the vaginal canal may point to a dermatologic diagnosis.

Lichen sclerosus causes white, thin, wrinkled patches on the vulva with intense itching. The tissue becomes fragile and may crack. It is estrogen-independent, occurs at any age, and requires topical high-potency corticosteroid treatment (typically clobetasol propionate 0.05%) [14].

Lichen planus can involve the vaginal mucosa itself, causing erosions, burning, and scarring that narrows the vaginal canal. Desquamative inflammatory vaginitis, a related entity, produces a copious yellow discharge alongside surface dryness and is often misdiagnosed as yeast infection [14].

Contact dermatitis from soaps, douches, laundry detergents, or fragranced products disrupts the vulvar barrier, creates inflammation, and produces a subjective sense of dryness. Eliminating the offending irritant resolves symptoms within two to four weeks in most cases.

Any vulvar dermatosis that goes undiagnosed can lead a clinician to prescribe vaginal estrogen for presumed GSM without addressing the true underlying condition. Biopsy should be considered when the clinical picture is atypical or does not respond to first-line therapy.

Breastfeeding and Postpartum Dryness

Lactation suppresses the hypothalamic-pituitary-ovarian axis through elevated prolactin levels. This produces a hypoestrogenic state similar in many respects to menopause, though it is temporary. Vaginal dryness during breastfeeding is common and expected.

The effect is dose-dependent. Exclusive breastfeeding suppresses estrogen more completely than partial breastfeeding. Most women recover normal vaginal lubrication within a few months after weaning, as ovarian cycling resumes [15].

For symptomatic relief during lactation, the American College of Obstetricians and Gynecologists (ACOG) recommends non-hormonal vaginal moisturizers as a first step [16]. Low-dose vaginal estrogen (estradiol 10 mcg inserts or estriol cream) is considered safe during breastfeeding because systemic absorption is minimal. Serum estradiol levels remain within the postmenopausal range with low-dose vaginal formulations [3].

How Clinicians Diagnose the Cause

Diagnosis starts with a detailed history. The clinician will ask about menstrual status, contraceptive use, medication list, breastfeeding, cancer treatment history, autoimmune disease, and the timing, character, and severity of symptoms.

Physical examination reveals objective signs. In GSM, the vaginal mucosa appears pale and thin, with loss of rugae (the normal folds). Petechiae may be visible. The tissue may bleed on contact with a cotton swab (the "friability" sign). Vaginal pH measured with indicator paper above 5.0 supports the diagnosis in the absence of infection [4].

Vaginal maturation index (VMI) quantifies the proportion of superficial, intermediate, and parabasal cells on a cytology smear. A shift toward parabasal cells confirms estrogen deficiency. This test is used primarily in clinical trials rather than routine practice.

Labs are targeted, not routine. A follicle-stimulating hormone (FSH) level above 30 mIU/mL and estradiol below 20 pg/mL confirm menopause when the clinical picture is unclear, such as in women who have had a hysterectomy and lack menstrual cessation as a marker. For suspected Sjögren syndrome, anti-SSA/Ro and anti-SSB/La antibodies, Schirmer's test, and salivary gland biopsy are the diagnostic workup [12].

Vulvar biopsy is reserved for cases with visible lesions, thickening, discoloration, or failure to respond to treatment. It distinguishes lichen sclerosus, lichen planus, and vulvar intraepithelial neoplasia from straightforward GSM.

Treatment Matched to the Underlying Cause

The right therapy depends entirely on the diagnosis. A blanket prescription for vaginal estrogen will miss medication-induced dryness, Sjögren syndrome, and vulvar dermatoses.

For GSM (estrogen-mediated dryness): Low-dose vaginal estrogen is the gold standard. Options include estradiol 10 mcg vaginal inserts (Imvexxy, Vagifem), conjugated estrogen cream (Premarin vaginal cream), and the estradiol vaginal ring (Estring, releasing 7.5 mcg/day for 90 days). A 2016 Cochrane review of 30 trials (6,235 women) concluded that all vaginal estrogen preparations were equally effective in relieving dryness and dyspareunia, with no significant differences in safety [17].

NAMS and ACOG both endorse local vaginal estrogen as first-line therapy for GSM, even in women with a history of breast cancer on a case-by-case basis, given the minimal systemic absorption [3][16].

Non-hormonal prescription alternatives: Ospemifene (Osphena), an oral selective estrogen receptor modulator (SERM), is FDA-approved for moderate-to-severe dyspareunia due to GSM. In a phase 3 trial (N=826), ospemifene 60 mg daily significantly reduced vaginal dryness and pain compared to placebo at 12 weeks [18]. Prasterone (Intrarosa), an intravaginal DHEA insert at 6.5 mg nightly, improved all GSM domains in the phase 3 ERC-238 trial (N=482) [19].

For medication-induced dryness: The first step is reviewing the medication list with the prescribing clinician. Switching from an SSRI to bupropion (which has a lower rate of sexual side effects), using a lower antihistamine dose, or choosing a non-anticholinergic bladder medication can reduce symptoms. Vaginal moisturizers (polycarbophil-based, hyaluronic acid-based) provide symptomatic relief while the medication is adjusted.

For autoimmune and dermatologic causes: Sjögren-related dryness requires long-acting vaginal moisturizers (applied 2 to 3 times weekly) and may benefit from systemic agents like hydroxychloroquine or pilocarpine. Lichen sclerosus is treated with clobetasol 0.05% ointment, typically nightly for 4 to 6 weeks followed by a maintenance schedule. Lichen planus involving the vagina may need intravaginal hydrocortisone suppositories or tacrolimus [14].

Over-the-counter options: Water-based or silicone-based lubricants provide immediate short-term relief during sexual activity. Long-acting vaginal moisturizers (Replens, Hyalo GYN) rehydrate the epithelium for 48 to 72 hours per application. Neither addresses the underlying cause, but both improve quality of life while a definitive diagnosis is established.

When Vaginal Dryness Needs Urgent Evaluation

Most vaginal dryness is not an emergency. But certain patterns warrant prompt medical attention.

Post-menopausal bleeding (any bleeding after 12 months of amenorrhea) requires evaluation to exclude endometrial pathology, regardless of whether dryness is also present. Vaginal dryness accompanied by recurrent UTIs (three or more per year) suggests significant urogenital atrophy that may benefit from prophylactic vaginal estrogen, which a 2008 Cochrane review found reduced UTI recurrence by approximately 50% compared to placebo [20].

Rapid onset of dryness in a woman under 40, especially with menstrual irregularity, points to possible premature ovarian insufficiency. This diagnosis carries implications beyond vaginal comfort: it increases the long-term risk of osteoporosis, cardiovascular disease, and cognitive decline, and it requires evaluation by a reproductive endocrinologist [13].

Vulvar lesions that do not respond to standard treatment within 8 to 12 weeks should be biopsied. Persistent unilateral thickening or discoloration can indicate vulvar intraepithelial neoplasia or, rarely, vulvar carcinoma.

Women receiving aromatase inhibitor therapy for breast cancer should have vaginal symptoms addressed proactively. The ACOG Committee Opinion 659 states that "fear of estrogen should not leave women without treatment options; non-hormonal therapies and, when appropriate, low-dose vaginal estrogen should be discussed" [16].